Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.22
+0.73002.76%
Post-market: 27.16-0.0600-0.22%19:59 EST
Volume:50.69M
Turnover:1.38B
Market Cap:154.76B
PE:20.01
High:27.37
Open:26.67
Low:26.52
Close:26.49
52wk High:27.69
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:0.72
T/O Rate:0.89%
Dividend:1.72
Dividend Rate:6.31%
EPS(TTM):1.36
EPS(LYR):1.36
ROE:8.58%
ROA:5.19%
PB:1.67
PE(LYR):19.95

Loading ...

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
17 hours ago

Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know

TIPRANKS
·
23 hours ago

Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016

TIPRANKS
·
23 hours ago

Pfizer says FDA grants Priority Review for sBLA for Hympavzi

TIPRANKS
·
Yesterday

FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren

Reuters
·
Yesterday

FDA Grants Priority Review for Hympavzi® (Marstacimab) Sbla for the Treatment of Two Hemophilia a or B Patient Populations With Significant Medical Need

THOMSON REUTERS
·
Yesterday

Pfizer - FDA Sets Pdufa Action Date for Hympavzi in Q2 2026

THOMSON REUTERS
·
Yesterday

White House Debuts Drug-Buying Site TrumpRx, With Roughly 40 Medications -- WSJ

Dow Jones
·
Yesterday

BRIEF-Pfizer Launches Cost Savings Program On TrumpRx Lowering Drug Costs For Millions Of Americans

Reuters
·
Yesterday

Pfizer: Program Offers Savings on Over 30 Brands Spanning Women's Health, Migraine, Arthritis, Rare Disease and More

THOMSON REUTERS
·
Yesterday

Pfizer Launches Cost Savings Program on Trumprx Lowering Drug Costs for Millions of Americans

THOMSON REUTERS
·
Yesterday

Pfizer Inc. (PFE US) - Obesity Pipeline De-Risking Drives Re-Rating Potential

Smartkarma
·
Yesterday

Pfizer Stock Forecast: Trending Analysts See Cautious Upside

TIPRANKS
·
Feb 05

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 05

Pfizer and BioNTech Pause modRNA Shingles Ambitions

TIPRANKS
·
Feb 05

Pfizer Price Target Maintained With a $27.00/Share by Cantor Fitzgerald

Dow Jones
·
Feb 05

BMO Capital Reaffirms Their Buy Rating on Pfizer (PFE)

TIPRANKS
·
Feb 04

Scotiabank Reaffirms Their Buy Rating on Pfizer (PFE)

TIPRANKS
·
Feb 04

BREAKINGVIEWS-Novo Nordisk’s falling knife is still gathering speed

Reuters
·
Feb 04

Balanced Near-Term Pipeline Upside Versus Structural Profit Headwinds Keeps Pfizer at Hold

TIPRANKS
·
Feb 04